{"id":521534,"date":"2021-08-02T16:09:53","date_gmt":"2021-08-02T20:09:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/"},"modified":"2021-08-02T16:09:53","modified_gmt":"2021-08-02T20:09:53","slug":"agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/","title":{"rendered":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LEXINGTON, Mass., Aug.  02, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8XFK9I1q_ewyCIzcnggS6x8BH_u7j77sO8PohluyQHlpcyD7QOuDuhHU8TGFYl1uykpZysG9WMp5t9PvVtimMw==\" rel=\"nofollow noopener\" target=\"_blank\">Agenus<\/a> (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.<\/p>\n<p>BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.<\/p>\n<p>\n        <strong><br \/>\n          <u>About Agenus<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer. The Company&#8217;s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Agenus Investor Relations<\/strong><br \/>\n        <br \/>Jan Medina, CFA<br \/>Agenus<br \/>781-674-4490<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6lonK2Q2H_-ndEYHsmEZlAgz_bEmZObYx19OC3qZpCXpFTMwQh5zS0GNQNv5723iVGMNs1wX_vextwmN156V0EyDuv34ZyJP7SoWxdvP7TU=\" rel=\"nofollow noopener\" target=\"_blank\">Jan.Medina@agenusbio.com<\/a><\/p>\n<p>\n        <strong>Agenus Media Relations<\/strong><br \/>\n        <br \/>Kimberly Ha<br \/>KKH Advisors<br \/>917-291-5744<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nD9jM7s7D3wrnwkY1myjtqMEkjl4QpTgZsQ1UU1TNCJ32fFrDpWmLT7dXpEoMEWUdtDmN9OhkBVZPSeWXYPurGqT7qGSi1t-OBl_0Sxqusq65dmk6O-f-PuSXnLA6nSb\" rel=\"nofollow noopener\" target=\"_blank\">kimberly.ha@kkhadvisors.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dfe1521f-e570-4297-a86b-f0b02cb1ad9c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer. The Company&#8217;s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521534","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer. The Company&#8217;s &hellip; Continue reading &quot;Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T20:09:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021\",\"datePublished\":\"2021-08-02T20:09:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/\"},\"wordCount\":249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/\",\"name\":\"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\",\"datePublished\":\"2021-08-02T20:09:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk","og_description":"LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer. The Company&#8217;s &hellip; Continue reading \"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T20:09:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021","datePublished":"2021-08-02T20:09:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/"},"wordCount":249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/","name":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=","datePublished":"2021-08-02T20:09:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTE3MiM0MzM3MDE2IzIwMjAwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521534"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}